For other salt forms or metabolites of 6-Bnz-cAMP please inquire. Site-selective and membrane-permeant activator of cAMP-dependent protein kinase (cAK) which does not activate Epac and thus can be used as an Epac-negative control. Increased metabolic stability against PDE compared to cAMP. Selects site A of both cAK isozymes and thus can be used for synergistic activation of type II when combined with site B II- selective analogues such as Sp-8-CPT-cAMPS (Cat. No. C 012) or 8-PIP-cAMP (Cat. No. P 002). For preferential stimulation of cAK type I a combination with the site B I-selective analogue 2-Cl-8-MA-cAMP (Cat. No. C 080) or 8-HA-cAMP (Cat. No. H 006) can be used. For more details on site selectivity please inquire. Detailed technical information and updated reference list available. References: Christensen et al., J. Biol. Chem., 278, 35394 - 35402 (2003); Bos, Trends Biochem. Sci., 31, 680 - 686 (2006).
Cat. No. | B 009 |
CAS number | [30275-80-0] |
Purity | > 98% HPLC |
Salt form | Sodium |
Storage temperature | -20°C / -4°F |
Molecular formula | C₁₇H₁₅N₅O₇P · Na |
Molecular weight [g/mol] | 455.3 |
Target | PKA (cAK) Activator |
Lipophilicity | 1.90 |
Absorption max [nm] | 279 |
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] | 19700 |